1. Home
  2. FUNC vs EDIT Comparison

FUNC vs EDIT Comparison

Compare FUNC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First United Corporation

FUNC

First United Corporation

HOLD

Current Price

$36.43

Market Cap

232.8M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.32

Market Cap

206.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUNC
EDIT
Founded
1900
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.8M
206.0M
IPO Year
2012
2016

Fundamental Metrics

Financial Performance
Metric
FUNC
EDIT
Price
$36.43
$2.32
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$4.92
AVG Volume (30 Days)
10.7K
1.6M
Earning Date
04-20-2026
03-09-2026
Dividend Yield
2.87%
N/A
EPS Growth
19.68
37.50
EPS
3.77
N/A
Revenue
$18,426,000.00
$31,937,000.00
Revenue This Year
$13.05
N/A
Revenue Next Year
$6.56
N/A
P/E Ratio
$9.54
N/A
Revenue Growth
4.01
132.64
52 Week Low
$24.80
$0.91
52 Week High
$41.95
$4.54

Technical Indicators

Market Signals
Indicator
FUNC
EDIT
Relative Strength Index (RSI) 46.20 53.26
Support Level $35.59 $1.84
Resistance Level $36.70 $2.36
Average True Range (ATR) 0.64 0.18
MACD 0.09 0.00
Stochastic Oscillator 32.57 52.91

Price Performance

Historical Comparison
FUNC
EDIT

About FUNC First United Corporation

First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: